SUPPLEMENTARY MATERIAL

Evaluation of *RAS* mutational status in liquid biopsy to monitor disease progression in metastatic colorectal cancer patients

Supplementary Table S1a,b: Tissue and plasma KRAS, according to survival and response

a)

N obs=36 (with available survival data and tissue KRAS data)	Tissue KRAS		
	WT	Mutated	p-value
Survived	13 (86.7%)	12 (57.1%)	0.077
Deceased	2 (13.3%)	9 (42.9%)	
N obs=32 (with available survival data and plasma KRAS data)	Plasma KRAS		
	WT	Mutated	p-value
Survived	5 (71.4%)	18 (72.0%)	1.000
Deceased	2 (28.6%)	7 (28.0%)	

b)

	Tissue KRAS			Plasma KRAS		
Response	**WT (n=17)**	**Mutated (n=26)**	**p-value**	**WT (n=9)**	**Mutated (n=29)**	**p-value**
Complete response	1 (5.9%)	2 (7.7%)	0.940	1 (11.1%)	2 (6.9%)	0.163
Partial response	2 (11.8%)	2 (7.7%)		2 (22.2%)	2 (6.9%)	
Stable disease	4 (23.5%)	4 (15.4%)		3 (33.3%)	4 (13.8%)	
Progressive disease	7 (41.2%)	13 (50.0%)		3 (33.3%)	14 (48.3%)	
TE	3 (17.7%)	5 (19.2%)		0	7 (24.1%)	

Supplementary Table S2a,b: Tissue and plasma NRAS, according to survival and response

a)

N obs=36 (with available survival data and tissue KRAS data)	Tissue NRAS		
	WT	**Mutated**	**p-value**
Survived	25 (69.4%)	0	-
Deceased	11 (30.6%)	0	
N obs=36 (with available survival data and plasma NRAS data)	**Plasma NRAS**		
	WT	**Mutated**	**p-value**
Survived	24 (70.6%)	1 (50.0%)	0.524
Deceased	10 (29.4%)	1 (50.0%)	

b)

	Tissue NRAS	**Plasma NRAS**		
Response	**WT (n=43)**	**WT (n=39)**	**Mutated (n=4)**	**p-value**
Complete response	3 (7.0%)	2 (5.1%)	1 (25.0%)	0.274
Partial response	4 (9.3%)	4 (10.3%)	0	
Stable disease	8 (18.6%)	8 (20.5%)	0	
Progressive disease	20 (46.5%)	17 (43.6%)	3 (75.0%)	
TE	8 (18.6%)	8 (20.5%)	0	